{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:24:50Z","timestamp":1787156690582,"version":"build-2736575974"},"reference-count":7,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:p>This nonrandomized clinical trial assesses the safety and efficacy of darolutamide, with or without concomitant lipid-modifying agents (LMAs), in treating nonmetastatic castration-resistant prostate cancer.<\/jats:p>","DOI":"10.1001\/jamanetworkopen.2026.29936","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:30:42Z","timestamp":1787153442000},"page":"e2629936","source":"Crossref","is-referenced-by-count":0,"title":["Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Murilo A.","family":"Luz","sequence":"first","affiliation":[{"name":"Hospital Erasto Gaertner, Curitiba, Brazil"},{"name":"Now with Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[{"name":"Urological Research Institute, IRCCS Ospedale San Raffaele and Universit\u00e0 Vita-Salute San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[{"name":"University of Melbourne and Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Pieczonka","sequence":"additional","affiliation":[{"name":"Associated Medical Professionals of NY, US Urology Partners, Syracuse, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Toho University Sakura Medical Center, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center and University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Artignan","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Priv\u00e9 Saint-Gr\u00e9goire, Saint-Gr\u00e9goire, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey T.","family":"Gotto","sequence":"additional","affiliation":[{"name":"Southern Alberta Institute of Urology, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle P.","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Urology Centers of Alabama, Homewood"},{"name":"Now with Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Malone","sequence":"additional","affiliation":[{"name":"First Urology, Jeffersonville, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Adorjan","sequence":"additional","affiliation":[{"name":"Bayer Consumer Care AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedeh","family":"Ghadessi","sequence":"additional","affiliation":[{"name":"Bayer HealthCare Pharmaceuticals, Inc, Whippany, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Verholen","sequence":"additional","affiliation":[{"name":"Bayer Consumer Care AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"13","key":"zld260162r1","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer.","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"zld260162r2","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide.","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"key":"zld260162r3","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-025-01047-7","article-title":"DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis.","author":"Yu","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"zld260162r4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","article-title":"Evaluation of clinically relevant drug\u2013drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial.","volume":"14","author":"Shore","year":"2019","journal-title":"Target Oncol"},{"issue":"6","key":"zld260162r5","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","article-title":"Drug\u2013drug interaction potential of darolutamide: in vitro and clinical studies.","volume":"44","author":"Zurth","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"10529","key":"zld260162r6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(25)01578-8","article-title":"Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.","volume":"407","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2026","journal-title":"Lancet"},{"issue":"3","key":"zld260162r7","doi-asserted-by":"publisher","first-page":"193.e7","DOI":"10.1016\/j.urolonc.2024.08.023","article-title":"Statin use and oncological outcomes in a propensity-matched cohort of nonmetastatic castration resistant prostate cancer patients of the ARAMIS trial.","volume":"43","author":"Chavarriaga","year":"2025","journal-title":"Urol Oncol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2853034\/luz_2026_ld_260162_1786556306.83717.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:30:42Z","timestamp":1787153442000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2853034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":7,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.29936","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}